MARKET

CMPS

CMPS

Compass Pathways Plc
NASDAQ
8.69
+0.08
+0.93%
Opening 09:31 11/09 EST
OPEN
8.87
PREV CLOSE
8.61
HIGH
8.99
LOW
8.67
VOLUME
171.73K
TURNOVER
--
52 WEEK HIGH
15.87
52 WEEK LOW
4.880
MARKET CAP
1.23B
P/E (TTM)
-4.1405
1D
5D
1M
3M
1Y
5Y
1D
Compass Pathways submitts NDA to FDA for COMP360 psilocybin
TipRanks · 3h ago
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), COMPASS Pathways (CMPS) and Zenas BioPharma, Inc. (ZBIO)
TipRanks · 3h ago
Compass Pathways Submits FDA New Drug Application For Comp360 Psilocybin For Treatment-Resistant Depression
Benzinga · 3h ago
Compass Pathways Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
Dow Jones · 3h ago
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $65 Price Target
Benzinga · 3h ago
Weekly Report: what happened at CMPS last week (1102-1106)?
Weekly Report · 5h ago
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Barchart · 9h ago
Compass Pathways’ Commercial Preparation Supports Outlook Despite Price-Target Cut to $16
TipRanks · 2d ago
More
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Webull offers Compass Pathways PLC (ADR) stock information, including NASDAQ: CMPS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPS stock methods without spending real money on the virtual paper trading platform.